U.S. National Institutes of Health
U.S. National Institutes of Health


IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
9489194891Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced ConstipationCompletedHas ResultsOpioid-Induced Constipation (OIC)Drug: NKTR-118|Drug: NKTR-118|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01323790
9489294892[Trial of device that is not approved or cleared by the U.S. FDA]WithheldNo Results Availablehttps://ClinicalTrials.gov/show/NCT01323777
9489394893ShuntCheck Versus Radionuclide in Evaluating Shunt Function in Symptomatic NPH PatientsRecruitingNo Results AvailableHydrocephalusDevice: ShuntCheck testhttps://ClinicalTrials.gov/show/NCT01323764
9489494894Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple MyelomaRecruitingNo Results AvailableMultiple MyelomaDrug: ACY-1215https://ClinicalTrials.gov/show/NCT01323751
9489594895Effect of Psychoeducation on Motivation to Change in Traumatized AlcoholicsCompletedNo Results AvailableAlcoholic Intoxication, ChronicBehavioral: Psychoeducationhttps://ClinicalTrials.gov/show/NCT01323738
9489694896Team-based Financial Incentives for Smoking CessationRecruitingNo Results AvailableTobacco Use DisorderBehavioral: Team-based financial incentiveshttps://ClinicalTrials.gov/show/NCT01323725
9489794897Vitamin D Supplementation and Cardiac Hypertrophy in Chronic Kidney Disease (CKD)Active, not recruitingNo Results AvailableChronic Kidney DiseaseDietary Supplement: Vitamin D Cholecalciferolhttps://ClinicalTrials.gov/show/NCT01323712
9489894898Behavioral Treatments for Anxiety and Depression in Veterans With Parkinson's DiseaseCompletedNo Results AvailableParkinson Disease|Anxiety|DepressionBehavioral: Cognitive Behavioral Therapyhttps://ClinicalTrials.gov/show/NCT01323699
9489994899Empiric Versus Imaging Guided Left Ventricular Lead Placement in Cardiac Resynchronization TherapyCompletedNo Results AvailableHeart FailureOther: Imaging guided optimal LV lead placementhttps://ClinicalTrials.gov/show/NCT01323686
9490094900Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.CompletedHas ResultsDermatitis, ChronicDrug: clobetasol propionate 0.05%|Drug: Vehicle / Placebohttps://ClinicalTrials.gov/show/NCT01323673
9490194901An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study BCompletedHas ResultsPulmonary Disease, Chronic ObstructiveDrug: GSK573719/GW642444 125/25|Drug: GSK573719/GW642444 62.5/25|Drug: GSK573719 125|Drug: GSK573719 62.5|Drug: GW642444 25|Device: placebohttps://ClinicalTrials.gov/show/NCT01323660
9490294902Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated ToddlersCompletedNo Results AvailablePoliomyelitisBiological: PoliorixTM|Biological: Infanrix+Hibhttps://ClinicalTrials.gov/show/NCT01323647
9490394903Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects WitCompletedHas ResultsPulmonary Disease, Chronic ObstructiveDrug: Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg|Drug: Fluticasone Propionate 250mcg/ salmeterol 50mcghttps://ClinicalTrials.gov/show/NCT01323634
9490494904Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects WithCompletedHas ResultsPulmonary Disease, Chronic ObstructiveDrug: Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg|Drug: Fluticasone Propionate 250mcg / salmeterol 50mcg|Drug: Double-dummy placebo|Drug: Salbutamol as neededhttps://ClinicalTrials.gov/show/NCT01323621
9490594905The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response StudyNot yet recruitingNo Results AvailableThalassemia MajorDrug: Vitamin D3|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01323608
9490694906Effectiveness of Celecoxib After Surgical Sperm RetrievalTerminatedHas ResultsPainDrug: Celecoxib|Drug: Sugar Pillhttps://ClinicalTrials.gov/show/NCT01323595
9490794907Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of GastroparesisTerminatedHas ResultsGastroparesisDrug: Erythromycin|Drug: Azithromycinhttps://ClinicalTrials.gov/show/NCT01323582
9490894908Abuse Potential of SativexCompletedNo Results AvailableEvaluation of Abuse Potential of SativexDrug: Sativex|Drug: Sativex|Drug: Sativex|Drug: Placebo|Drug: Marinol|Drug: Marinolhttps://ClinicalTrials.gov/show/NCT01323569
9490994909Mechanisms of Panic Disorders TreatmentRecruitingNo Results AvailablePanic Disorder|Agoraphobia|Panic AttacksBehavioral: Cognitive Behavioural Therapy (CBT)|Behavioral: Cognitive Behavioural Therapy (CBT)https://ClinicalTrials.gov/show/NCT01323556
9491094910Safety and Performance of the Elaspine System in the Treatment of the Lumbar SpineRecruitingNo Results AvailableLower Back PainDevice: Elaspineâ„¢https://ClinicalTrials.gov/show/NCT01323543
9491194911A Phase 1b/2, Multicenter, Randomized, Open-Label, Dose-Escalation and Confirmation Study of Eribulin in Combination With CapecitabineActive, not recruitingNo Results AvailableMetastatic Breast CancerDrug: Eribulin mesylate administration as a 2 to 5 min IV infusion at on Day 1|Drug: Eribulin mesylate administration as a 2 to 5 min IV infusion on Day 1 and Day 8https://ClinicalTrials.gov/show/NCT01323530
9491294912Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The ExtremityRecruitingNo Results AvailableMelanomaDrug: Ipilimumab, Melphalan and Dactinomycinhttps://ClinicalTrials.gov/show/NCT01323517
9491394913Pain and Music Therapy in Patients Suffering ArteritisNot yet recruitingNo Results AvailableArteritisOther: Music|Other: no musichttps://ClinicalTrials.gov/show/NCT01323504
9491494914"EASY EFFECTIVE SMOKELESS" With NICORETTE®CompletedNo Results AvailableStereotyped Behavior|Tobacco Smoking BehaviorDrug: Nicotine replacement therapyhttps://ClinicalTrials.gov/show/NCT01323491
9491594915Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in AdultsCompletedHas ResultsMajor Depressive DisorderDrug: Vortioxetine (Lu AA21004)https://ClinicalTrials.gov/show/NCT01323478
9491694916Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of SativexCompletedNo Results AvailableEvaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4|Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4|Evaluation of Pharmacokinetics of Sativex in the AbsenDrug: Sativex and rifampicin|Drug: Sativex and rifampicin|Drug: Sativex and ketoconazole|Drug: Sativex and ketoconazole|Drug: Sativex and omeprazole|Drug: Sativex and omeprazolehttps://ClinicalTrials.gov/show/NCT01323465
9491794917Entecavir for Chronic Hepatitis BCompletedNo Results AvailableEntecavir for Chronic Hepatitis B PatientsDrug: Entecavirhttps://ClinicalTrials.gov/show/NCT01323452
9491894918Axiumâ„¢ MicroFXâ„¢ for Endovascular Repair of IntraCranial Aneurysm-A Multicenter StudyRecruitingNo Results AvailableAneurysmDevice: Axiumâ„¢ MicroFXâ„¢ PGLA COILShttps://ClinicalTrials.gov/show/NCT01323439
9491994919Treatment of Stress Urinary Incontinence by Injection of Autologous Muscle Fibers Into the Urethral Sphincter.Active, not recruitingNo Results AvailableUrinary Incontinence, StressProcedure: Periurethral injectionhttps://ClinicalTrials.gov/show/NCT01323426
9492094920Determinants of Penumbra in Acute Ischemic Stroke PatientsRecruitingNo Results AvailableAcute Ischemic Strokehttps://ClinicalTrials.gov/show/NCT01323413

* Görseller ve İçerik tekif hakkına sahip olabilir